financetom
Business
financetom
/
Business
/
Stability AI to lay off staff weeks after founder Mostaque resigned as CEO - memo
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stability AI to lay off staff weeks after founder Mostaque resigned as CEO - memo
Apr 18, 2024 6:10 AM

April 18 (Reuters) - Stability AI will lay off some

staff as part of a restructuring process, according to an

internal memo seen by Reuters on Thursday as well as a person

familiar with the matter, weeks after founder Emad Mostaque

resigned as CEO.

The move signals another shift for the AI startup after

Mostaque's departure as chief executive and member of the

company's board, in the face of stiff competition from firms

like ChatGPT-maker OpenAI and French startup Mistral.

Mostaque stepped down from the board of the company, which

makes the Stable Diffusion image-generation tool, in March, to

pursue decentralized AI.

"These decisions have not been taken lightly and they are

intended to right-size parts of the business and focus our

operations, which is critical to setting us on a more

sustainable path," Interim co-CEOs Shan Shan Wong and Christian

Laforte said in an internal memo to employees.

The company, which has also released AI models to

generate audio and video using text prompts, said last October

that it had nearly 200 employees around the world.

The employees affected by the layoffs will be informed

individually and the U.K.-based company will hold a regular

townhall on Thursday, the memo said.

However, the number of staffers to be laid off was not

disclosed.

Stability AI counts venture capital firm Lightspeed

Venture Partners, actor Ashton Kutcher's Sound Ventures,

investment management firm Coatue and chipmaker Intel ( INTC )

as investors, according to data firms Crunchbase and Pitchbook.

The British firm made its Stable Diffusion 3 model

available to developers on Wednesday through an application

programming interface.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved